Capivasertib inhibits a key pathway in metastatic breast cancer

Affiliations

¹ Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
² Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA. Electronic address: brufskyam@upmc.edu.

Free article

Comment

Azadeh Nasrazadani et al. Lancet Oncol. 2020 Mar.

Free article

. 2020 Mar;21(3):318-319.

doi: 10.1016/S1470-2045(19)30857-5. Epub 2020 Feb 5.

¹ Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
² Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA. Electronic address: brufskyam@upmc.edu.

No abstract available

Comment on

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, Madden TA, Bale C, Bezecny P, Joffe J, Moon S, Twelves C, Venkitaraman R, Waters S, Foxley A, Howell SJ. Jones RH, et al. Lancet Oncol. 2020 Mar;21(3):345-357. doi: 10.1016/S1470-2045(19)30817-4. Epub 2020 Feb 5. Lancet Oncol. 2020. PMID: 32035020 Free PMC article. Clinical Trial.